MPL and autoimmune thrombocytopenic purpura: The successful combination of thrombopoietin receptor agonists (TRAs) like romiplostim with warfarin offers a promising therapeutic strategy for ITP patients needing ongoing anticoagulation, especially those unsuitable for standard treatments or with inadequate responses to typical therapies.